Hypertonic Saline for Acute Bronchiolitis

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether nebulized 3% hypertonic saline (HS) improves respiratory distress in children 2-23 months presenting to the emergency department (ED) with acute bronchiolitis with persistent respiratory distress after initial therapy with a trial of nebulized albuterol.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital of Philadelphia
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Age 8 weeks through 23 months

• First episode of wheezing associated with respiratory distress and upper respiratory tract infection.

• Respiratory Distress Assessment Instrument (RDAI) rating of ≥4 and ≤15 after initial albuterol nebulization per standard care

• Pediatric Emergency Medicine (PEM) physician does not plan additional bronchodilator therapy within the hour after initial assessment.

• Parental/guardian permission (informed consent)

Exclusion Criteria:

• Subjects with prior history of wheezing or asthma or who have received bronchodilator therapy prior to the current illness

• Chronic lung or heart disease

• Critically ill infants requiring immediate airway stabilization

• Non-English speaking parent/guardian

• Inability to take nebulized medications